Business News

MEI Pharma and Helsinn Group Discontinue Phase 3 Study of Pracinostat in AML After Interim Analysis

Lugano, Switzerland and San Diego, USA, July 2, 2020 – Helsinn, a Swiss pharmaceutical group focused on building quality cancer care and rare diseases products, and MEI Pharma, Inc. (Nasdaq: MEIP), a late-stage pharmaceutical company focused on advancing potential new therapies for cancer, today announce that an interim futility analysis of …

Read More »

Alexion Completes Acquisition of Portola Pharmaceuticals

BOSTON–(BUSINESS WIRE)–Alexion Pharmaceuticals, Inc. (NASDAQ:ALXN) today announced the successful completion of its acquisition of Portola Pharmaceuticals, Inc. (NASDAQ:PTLA). The acquisition adds Factor Xa inhibitor reversal agent Andexxa® [coagulation factor Xa (recombinant), inactivated-zhzo], marketed as Ondexxya® in Europe, to Alexion’s commercial portfolio. Andexxa is the first and only approved Factor Xa inhibitor reversal agent …

Read More »

Sarepta Therapeutics Signs Agreement with Hansa Biopharma for Imlifidase as a Pre-Treatment Ahead of Gene Therapy in Select Indications

CAMBRIDGE, Mass., July 02, 2020 (GLOBE NEWSWIRE) — Sarepta Therapeutics, Inc. (NASDAQ:SRPT), the leader in precision genetic medicine for rare diseases, today announced an agreement with Hansa Biopharma, the leader in immunomodulatory enzyme technology for rare Immunoglobulin G (IgG) mediated diseases, for imlifidase. Under the terms of the agreement, Sarepta …

Read More »

Ipsen Joins Collaboration to Evaluate Cabozantinib Plus Atezolizumab in Metastatic NSCLC and Metastatic Castration-Resistant Prostate Cancer

Ipsen (Euronext: IPN; ADR: IPSEY), today announced it will join the Exelixis and Roche clinical collaboration and participate in the funding of the recently initiated CONTACT-01 and CONTACT-02 global Phase III pivotal trials. CONTACT-01 is evaluating the safety and efficacy of cabozantinib (CABOMETYX®) in combination with atezolizumab (TECENTRIQ®) in patients …

Read More »

Carmine Therapeutics and Takeda Collaborate to Develop Rare Disease Gene Therapies Using Novel Red Blood Cell Extracellular Vesicles Platform

CAMBRIDGE, Mass., June 30, 2020 /PRNewswire/ — Carmine Therapeutics announced today that it has signed a research collaboration agreement with Takeda Pharmaceutical Company Limited (“Takeda”) to discover, develop and commercialize transformative non-viral gene therapies for two rare disease targets using Carmine’s REGENT(TM) technology, based on red blood cell extracellular vesicles. …

Read More »

Aldevron Announces Agreement with Ziopharm Oncology for neoGMP Production of Sleeping Beauty Plasmid DNA to Express TCRs for Treatment of Solid Tumors

FARGO, N.D.–(BUSINESS WIRE)–Aldevron, a leading provider of products and services for the biotechnology industry, today announced an agreement with Ziopharm Oncology to produce plasmid DNA for T cell therapy of solid tumors. Aldevron has developed the neoGMP® service level designed to address this new and rapidly growing market. “We are pleased …

Read More »

Sosei Heptares and AbbVie Announce New Discovery Collaboration Targeting Inflammatory Diseases

Tokyo, Japan and London, UK, 25 June 2020 – Sosei Group Corporation (“the Company”; TSE: 4565) announces that it has entered into an exclusive discovery collaboration and option to license agreement with AbbVie (NYSE: ABBV), a research-based global biopharmaceutical company, to discover, develop and commercialize novel medicines that modulate G protein-coupled …

Read More »

CSL Behring to Pay $450 Million to Aquire uniQure’s Late-Stage Hemophilia B Gene Therapy

KING OF PRUSSIA, Pa., – 24 June 2020 – Global biotherapeutics leader CSL Behring announced today that it has agreed to acquire exclusive global license rights to commercialize an adeno-associated virus (AAV) gene therapy program, AMT-061 (etranacogene dezaparvovec), for the treatment of hemophilia B from uniQure (NASDAQ: QURE), a leading gene therapy company. The AMT-061 …

Read More »

Merck Enters Research Collaboration and License Agreement with Yumanity Focused on New Treatments for Neurodegenerative Diseases

CAMBRIDGE, Mass., June 24, 2020 (GLOBE NEWSWIRE) — Yumanity Therapeutics, a leader in the discovery and development of innovative, disease-modifying therapies for neurodegenerative diseases, today announced that it has entered into a strategic research collaboration and license agreement with Merck (known as MSD outside the United States and Canada) focused …

Read More »

Gilead Sciences Secures Exclusive Option to Acquire Pionyr Immunotherapeutics

FOSTER CITY, Calif. & SOUTH SAN FRANCISCO, Calif.–(BUSINESS WIRE)–Gilead Sciences, Inc. (Nasdaq: GILD) announced today that for $275 million the company will acquire a 49.9 percent equity interest in Pionyr Immunotherapeutics Inc., a privately held company developing first-in-class cancer immunotherapies, and an exclusive option to purchase the remainder of Pionyr. …

Read More »